Lite Strategy, Inc. Increase (Decrease) in Contract with Customer, Asset
Lite Strategy, Inc. (LITS) reported Increase (Decrease) in Contract with Customer, Asset of $2.57 million for the 6-month period ending 2021-12-31, per its 10-Q/A filed 2022-05-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2022-05-23
- Lite Strategy, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2021-12-31 was $2.03M, a 59.09% decline year-over-year.
- Lite Strategy, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2021-09-30 was $538.00K, a 73.90% decline year-over-year.
- Lite Strategy, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2020-12-31 was $4.96M, a 41275.00% increase year-over-year.
- Lite Strategy, Inc. increase (decrease) in contract with customer, asset for the quarter ending 2020-09-30 was $2.06M.
- Lite Strategy, Inc. increase (decrease) in contract with customer, asset for fiscal 2020 was -$82.00K, a 121.93% decline from fiscal 2019.
- Lite Strategy, Inc. increase (decrease) in contract with customer, asset for fiscal 2019 was $374.00K.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 3 month as first filed | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 6 month as first filed | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|---|---|
| 2021-12-31 | $2.03M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2022-05-23 | $2.57M 10-Q/A · filed 2022-05-23 | ||||
| 2021-09-30 | $538.00K 10-Q/A · filed 2022-05-23 | |||||
| 2020-12-31 | $4.96M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2022-05-23 | $7.03M 10-Q/A · filed 2022-05-23 | $9.60M 10-Q · filed 2021-02-04 | $7.12M derived: sum of 3 quarters · filed 2022-05-23 | $7.15M derived: sum of 4 quarters · filed 2022-05-23 | |
| 2020-09-30 | $2.06M 10-Q/A · filed 2022-05-23 | $4.78M 10-Q · filed 2020-11-10 | $2.15M derived: sum of 2 quarters · filed 2022-05-23 | $2.18M derived: sum of 3 quarters · filed 2022-05-23 | $2.20M derived: sum of 4 quarters · filed 2022-05-23 | |
| 2020-06-30 | $92.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-09 | $123.00K derived: sum of 2 quarters · filed 2020-09-09 | $135.00K derived: sum of 3 quarters · filed 2021-02-04 | -$82.00K 10-K · filed 2020-09-09 | ||
| 2020-03-31 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-07 | $43.00K derived: sum of 2 quarters · filed 2021-02-04 | -$174.00K 10-Q · filed 2020-05-07 | $115.00K derived: sum of 4 quarters · filed 2021-02-04 | ||
| 2019-12-31 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-04 | -$205.00K 10-Q · filed 2021-02-04 | $84.00K derived: sum of 3 quarters · filed 2021-02-04 | $78.00K derived: sum of 4 quarters · filed 2021-02-04 | ||
| 2019-09-30 | -$217.00K 10-Q · filed 2020-11-10 | $72.00K derived: sum of 2 quarters · filed 2020-11-10 | $66.00K derived: sum of 3 quarters · filed 2020-11-10 | $89.00K derived: sum of 4 quarters · filed 2020-11-10 | ||
| 2019-06-30 | $289.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-09 | $283.00K derived: sum of 2 quarters · filed 2020-09-09 | $306.00K derived: sum of 3 quarters · filed 2020-09-09 | $374.00K 10-K · filed 2020-09-09 | ||
| 2019-03-31 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-09 | $17.00K derived: sum of 2 quarters · filed 2019-05-09 | $85.00K 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-07 | $91.00K 10-Q · filed 2019-02-07 | ||||
| 2018-09-30 | $68.00K 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |